Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHKCIS)

Drug Name
Aldoxorubicin Drug Info
Synonyms
1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione
Indication
Disease Entry ICD 11 Status REF
Soft tissue sarcoma 2B57 Phase 3 [1]
Glioblastoma multiforme 2A00.0 Phase 2 [2]
Pancreatic ductal carcinoma 2C10.0 Phase 2 [2]
Small-cell lung cancer 2C25.Y Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Cross-matching ID
PubChem CID
9810709
CAS Number
CAS 1361644-26-9
TTD Drug ID
DMHKCIS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting DNA topoisomerase II (TOP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [5]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [6]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [5]
Mitoxantrone DMM39BF Acute myelogenous leukaemia 2A41 Approved [7]
Idarubicin DMM0XGL Acute myelogenous leukaemia 2A41 Approved [5]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [5]
Lomefloxacin DMVRH9C Bacterial infection 1A00-1C4Z Approved [8]
Dexrazoxane DMD7X1O Breast cancer 2C60-2C65 Approved [5]
Podofilox DMT2EJP Condyloma 1A95 Approved [9]
Enoxacin DMYTE6L Acute gonococcal cervicitis Approved [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [4]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01580397) Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer. U.S. National Institutes of Health.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
7 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
8 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
9 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
10 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.